Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2013

View Archived Issues

Novel protease inhibitors exhibit broad-spectrum antiviral activity

A potential new biomarker for predicting recurrence of HCC

Exelixis describes discovery of a novel small-molecule mTOR inhibitor

AbbVie initiates phase III renal outcomes study of atrasentan in diabetic nephropathy

RaQualia reports data from first-in-human study of RQ-00000010

Grant supports development of Metabolomic Technologies' colonic polyp screening test

Pasireotide may have potential in treatment of postoperative dumping syndrome

Mucosis presents preclinical SynGEM data

Actavis to acquire Warner Chilcott

Baxter obtains marketing approval in Europe for HyQvia

Biogen Idec submits BLA to FDA for Plegridy in multiple sclerosis

Grifols and Aradigm agree for Pulmaquin and possible partial stock adquisition

Intercell obtains approval for Ixiaro in pediatric patients in the U.S.

New orexin OX2 receptor antagonists prepared at Merck & Co.

KineMed and MedImmune to study protein dynamics in neurodegenerative diseases

Galderma presents new CXCR2 receptor antagonists

Liquidia Technologies extends collaboration with PATH

Pharmaxis meets with the FDA regarding path to approval for Bronchitol

Merck & Co. synthesizes novel ROMK blockers

Sorrento Therapeutics receives continued NIAID support

New mGlu receptor modulators divulged by Merck & Co.

Recombinant LCAT replacement therapy mobilizes excess cholesterol from tissue in vivo

UCB and IBM collaborate on personalize care for epilepsy

NicOx patents new nitric oxide donors

Chinese researchers patent new tyrosine-protein kinase inhibitors

EMA grants accelerated assessment to Gilead's MAA for sofosbuvir

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...